GILD
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Gilead and PAHO announced a milestone partnership to accelerate access to twice-yearly lenacapavir for HIV prevention across Latin America and the CaribbeanSep 15, 2026
- FDA approved Gilead's Bixlenvo, a new once-daily single-tablet option for virologically suppressed adults with HIVAug 28, 2026
- The European Commission expanded Trodelvy's first-line role in metastatic triple-negative breast cancer regardless of PD-L1 statusAug 24, 2026
- CHMP recommends Trodelvy plus Keytruda for first-line PD-(L)1-positive metastatic triple-negative breast cancerJul 24, 2026
- Weekly oral HIV regimen of islatravir and lenacapavir maintains viral suppression in adults switching therapyJul 22, 2026